Experic
Contract Manufacturing Organisation and Pharmaceutical Supply Services
The COVID-19 pandemic has presented several operational challenges for the pharmaceutical and healthcare industry.
The COVID-19 pandemic has presented several operational challenges for the pharmaceutical and healthcare industry.
GlobalData had conducted a survey to identify how the COVID-19 pandemic affected clinical trial planning for clinical trial sponsors, collaborators or contract research organisations (CROs).
An analysis of the survey reveals that 30% of the respondents believe that the pandemic would impact patient recruitment, while 17% of the companies felt that investigator recruitment would be affected.
Impact of COVID-19 Social Distancing Measures on Clinical Trials
Another 17% of the respondents highlighted that the pandemic will disrupt the supply of clinical trial materials due to restrictions and lockdowns measures.
Furthermore, 14% of the respondents are planning to either cancel or postpone trials, while another 10% opnied that regulator resources are stretched amid the pandemic.
Around 5% of the surveyed companies are mulling to change the location of the trial, while 4% noted that they have no clinical trials planned in the next two years.
Only 4% of the respondents said that the COVID-19 pandemic will not affect their trial programmes.
GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.
Find out moreThe analysis is based on responses received from the GlobalData Coronavirus Survey – Pharmaceutical Imports/Exports and Supply Chain, 2020 conducted between 13 March and 24 March 2020.
Contract Manufacturing Organisation and Pharmaceutical Supply Services
Nanofibre and Nanoparticle Production Systems
Customised Clinical Supply and Biological Sample Services